[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537555":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":16,"studyPopulation":16,"armGroups":28,"interventions":39,"overallOfficials":43,"centralContacts":48,"locations":57,"responsibleParty":76,"collaborators":79,"id":81,"slug":16,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":16,"eligibilityCriteria":85,"healthyVolunteers":82,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":16,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":16,"overallStatus":60,"whyStopped":16,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Xinqiao Hospital of Chongqing","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"ETS","Early tumor shrinkage","8 weeks",[14,17,19],{"measure":15,"description":16,"timeFrame":12},"ORR",null,{"measure":18,"description":16,"timeFrame":12},"DCR",{"measure":20,"description":16,"timeFrame":21},"PFS","1 year",{"allocation":23,"interventionModel":24,"interventionModelDescription":16,"primaryPurpose":25,"observationalModel":16,"timePerspective":16,"maskingInfo":26},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":27,"maskingDescription":16,"whoMasked":16},"NONE",[29,35],{"label":30,"type":31,"description":32,"interventionNames":33},"Test group","EXPERIMENTAL","Thalidomide+cetuximab+FOLFOX\u002FFOLFIRI",[34],"Drug: Thalidomide+cetuximab+FOLFOX\u002FFOLFIRI",{"label":36,"type":37,"description":38,"interventionNames":16},"control group","NO_INTERVENTION","cetuximab+FOLFOX\u002FFOLFIRI",[40],{"type":41,"name":32,"description":32,"armGroupLabels":42,"otherNames":16},"DRUG",[30],[44],{"name":45,"affiliation":46,"role":47},"rui kong, doctor","Chongqing Medical University","PRINCIPAL_INVESTIGATOR",[49,54],{"name":50,"role":51,"phone":52,"phoneExt":16,"email":53},"Jianguo Sun, doctor","CONTACT","023-68774490","sunjianguo@tmmu.edu.cn",{"name":45,"role":51,"phone":55,"phoneExt":16,"email":56},"15823688918","kongruiok@163.com",[58],{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"the second affiliated hospital of Army medical university","RECRUITING","Chongqing","Chongqing Municipality","400037","China","CN",{"type":67,"coordinates":68},"Point",[69,70],106.55771,29.56026,{"lat":70,"lon":69},[73],{"name":74,"role":51,"phone":52,"phoneExt":16,"email":75},"jianguo Sun, Phd","sunjg09@aliyun.com",{"type":47,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":16,"oldOrganization":16},"Jianguo Sun","Deputy director of oncology department, Clinical Professor",[80],{"name":46,"class":6},"100537555",false,"NCT06279351","Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer","Inclusion Criteria:\n\n1. Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue\u002Fcytology and genetic testing;\n2. Physical state is good: PS 0-2;\n3. Expected survival of more than 3 months;\n4. Aged 18-75 years old;\n5. Have not received systematic chemotherapy before;\n6. Did not receive cetuximab treatment;\n7. Liver, kidney and bone marrow functions are basically normal;\n8. The clearance period of chemotherapy and molecular targeted therapy is more than 4 weeks;\n9. Voluntary participation in the group, good compliance, can cooperate with the experiment observation, and sign the written informed consent.\n\nExclusion Criteria:\n\n1. Patients with severe dysfunction of vital organs (heart, liver, kidney);\n2. Patients with other malignant tumors;\n3. Patients who are pregnant or breastfeeding (women of childbearing age need to check pregnancy test);\n4. In the active phase of acute or chronic infectious diseases;\n5. People with a clear history of drug allergy or allergic constitution;\n6. Patients participating in other clinical trials;\n7. Other conditions in which the patient was considered inappropriate to participate in the study.","ALL","18 Years","75 Years",{"count":90,"type":91},96,"ESTIMATED","INTERVENTIONAL",[94],"PHASE2","1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequent large-scale research and clinical application.\n2. To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab +FOLFIRI, so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies.",[84],"2025-07-11",{"date":99,"type":100},"2025-07-14","ACTUAL",{"date":102,"type":100},"2024-08-11",{"date":104,"type":91},"2025-12-31",{"name":5,"class":6},1]